Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders

a technology of amidoisothiazole and compounds, which is applied in the field of therapeutic compounds, can solve the problems of a substantial risk of cardiovascular diseas

Inactive Publication Date: 2012-04-19
THE UNIV COURT OF THE UNIV OF EDINBURGH
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These abnormalities confer a substantial risk of cardiovascular disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders
  • Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders
  • Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders

Examples

Experimental program
Comparison scheme
Effect test

examples of specific embodiments

[0621]In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:

Code No.SynthesisStructureAA-0123AA-0224

[0622]In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:

Code No.SynthesisStructureBB-017BB-0213BB-034

[0623]In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:

CodeNo.SynthesisStructureCC-0116CC-0212

Substantially Purified Forms

[0624]One aspect of the present invention pertains to AITZ compounds, as described herein, in substantially purified form and / or in a form substantially free from contaminants.

[0625]In one embodiment, the compound is in substantially purified form and / or in a form substantially free from contaminants.

[0626]In one embodiment, the compound is in a substant...

examples

[0728]The following examples are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein.

Analytical Method 1:

[0729]The system consisted of a Hewlett Packard HP1100 LC system and a Higgins Clipeus 5 μm C18 100×3.0 mm column. Detection was achieved using a Micromass ZQ quadrupole electrospray (positive and negative ion), a UV detector at 254 nm and a Sedex ELS 85 evaporative light scattering detector. Mobile Phase A: 0.1% aqueous formic acid, Mobile Phase B: 0.1% formic acid in MeCN. Flow rate 1 mL / min: Gradient: 0-1 min 5% B; 1-15 min 5-95% B; 15-20 min 95% B; 20-22 min 95-5% B; 22-25 min 95% B.

Analytical Method 2:

[0730]The system consisted of a Finnigan AQA single quadrupole mass spectrometer linked to a Hewlett Packard 1050 LC system with UV diode array detector and autosampler and using a Luna 3 μm C18(2) 30×4.6 mm column or equivalent. The spectrometer had an electrospray source operating in positive ion mo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

Description

RELATED APPLICATION[0001]This application is related to U.S. provisional patent application No. 61 / 186,963 filed 15 Jun. 2009, the contents of which are incorporated herein by reference in their entirety.TECHNICAL FIELD[0002]The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular diso...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4709C07D417/14A61K31/427C12N9/99A61P43/00A61P3/10A61P3/08A61P3/04A61P3/06A61P9/10A61P9/00A61P3/00A61P1/16A61P25/00A61P25/18A61P25/28A61P25/16A61P1/18A61P27/06A61P25/22A61P25/24A61P29/00A61P19/10A61P9/12A61P27/02A61P11/06A61P11/00A61P17/00A61P1/00A61P19/02C07D413/06
CPCC07D417/14C07D417/06A61P1/00A61P1/16A61P1/18A61P3/00A61P3/04A61P3/06A61P3/08A61P3/10A61P9/00A61P9/10A61P9/12A61P11/00A61P11/06A61P17/00A61P19/02A61P19/10A61P25/00A61P25/16A61P25/18A61P25/22A61P25/24A61P25/28A61P27/02A61P27/06A61P29/00A61P43/00
Inventor WEBSTER, SCOTT PETERSECKL, JONATHAN ROBERTWALKER, BRIAN ROBERTWARD, PETERPALLIN, THOMAS DAVIDDYKE, HAZEL JOANPERRIOR, TREVOR ROBERT
Owner THE UNIV COURT OF THE UNIV OF EDINBURGH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products